Cytokinetics (CYTK) Misses Q2 EPS by 20c, misses on revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $62.03 -1.52%
EPS Growth %: +43.1%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +43.1%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.34), $0.20 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $5.67 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Waystar Holding Corp. (WAY) Reports Q3 EPS of $0.44
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
